Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

ALNY has been the topic of several other research reports. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research note on Friday, August 1st. Truist Financial began coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $385.00 target price on the stock. The Goldman Sachs Group lifted their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a research note on Tuesday, September 16th. Evercore ISI lifted their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research note on Thursday, September 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Saturday, September 27th. Twenty-four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $439.58.

Alnylam Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ ALNY opened at $456.35 on Friday. The company has a market cap of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $484.21. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock’s 50 day simple moving average is $441.57 and its 200 day simple moving average is $338.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business’s revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insiders Place Their Bets

In related news, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the transaction, the director directly owned 775 shares in the company, valued at $362,390. The trade was a 95.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the transaction, the chief executive officer owned 65,409 shares in the company, valued at $29,568,138.45. The trade was a 12.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,144 shares of company stock worth $44,160,261. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. SVB Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth $27,000. Bessemer Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 69 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $30,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $37,000. Finally, Ameritas Advisory Services LLC purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $42,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.